Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model

PurposeTo study the correlation of intestinal absorption for drugs with various absorption routes between human and rat, and to explore the underlying molecular mechanisms for the similarity in drug intestinal absorption and the differences in oral bioavailability between human and rat.Materials and MethodsThe intestinal permeabilities of 14 drugs and three drug-like compounds with different absorption mechanisms in rat and human jejunum were determined by in situ intestinal perfusion. A total of 48 drugs were selected for oral bioavailability comparison. Expression profiles of transporters and metabolizing enzymes in both rat and human intestines (duodenum and colon) were measured using GeneChip analysis.ResultsNo correlation (r2 = 0.29) was found in oral drug bioavailability between rat and human, while a correlation (r2 = 0.8) was observed for drug intestinal permeability with both carrier-mediated absorption and passive diffusion mechanisms between human and rat small intestine. Moderate correlation (with r2 > 0.56) was also found for the expression levels of transporters in the duodenum of human and rat, which provides the molecular mechanisms for the similarity and correlation of drug absorption between two species. In contrast, no correlation was found for the expressions of metabolizing enzymes between rat and human intestine, which indicates the difference in drug metabolism and oral bioavailability in two species. Detailed analysis indicates that many transporters (such as PepT1, SGLT-1, GLUT5, MRP2, NT2, and high affinity glutamate transporter) share similar expression levels in both human and rat with regional dependent expression patterns, which have high expression in the small intestine and low expression in the colon. However, discrepancy was also observed for several other transporters (such as MDR1, MRP3, GLUT1, and GLUT3) in both the duodenum and colon of human and rat. In addition, the expressions of metabolizing enzymes (CYP3A4/CYP3A9 and UDPG) showed 12 to 193-fold difference between human and rat intestine with distinct regional dependent expression patterns.ConclusionsThe data indicate that rat and human show similar drug intestinal absorption profiles and similar transporter expression patterns in the small intestine, while the two species exhibit distinct expression levels and patterns for metabolizing enzymes in the intestine. Therefore, a rat model can be used to predict oral drug absorption in the small intestine of human, but not to predict drug metabolism or oral bioavailability in human.

[1]  Paul W. Buehler,et al.  Comparison of Oral Absorption and Bioavailability of Drugs Between Monkey and Human , 2002, Pharmaceutical Research.

[2]  K. Takara,et al.  Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAS in small intestine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[3]  B. H. Migdalof,et al.  Pharmacokinetics of Captopril in Healthy Subjects and in Patients with Cardiovascular Diseases , 1988, Clinical pharmacokinetics.

[4]  Y. Sugiyama,et al.  cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3) 1 , 1998 .

[5]  D. Smith,et al.  The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. , 1998, British journal of clinical pharmacology.

[6]  W Krause,et al.  Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences. , 1983, Drug metabolism and disposition: the biological fate of chemicals.

[7]  L. Benet,et al.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.

[8]  T. Baillie,et al.  Is the role of the small intestine in first-pass metabolism overemphasized? , 1999, Pharmacological reviews.

[9]  Hans Lennernäs,et al.  Comparison Between Permeability Coefficients in Rat and Human Jejunum , 1996, Pharmaceutical Research.

[10]  J. M. Shaw,et al.  Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. , 1981, Journal of pharmaceutical sciences.

[11]  H Lennernäs,et al.  Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.

[12]  S. Takenoshita,et al.  Immuno-localization of H+/peptide cotransporter in rat digestive tract. , 1996, Biochemical and biophysical research communications.

[13]  K. Terada,et al.  Interaction of tri-O-methyl-beta-cyclodextrin with drugs. II. Enhanced bioavailability of ketoprofen in rats when administered with tri-O-methyl-beta-cyclodextrin. , 1983, Chemical & pharmaceutical bulletin.

[14]  H Lennernäs,et al.  Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag. , 1999, Acta physiologica Scandinavica.

[15]  M. Iwaki,et al.  Bioavailability of indomethacin calcium and magnesium, and effect of the salts on drug metabolizing enzyme activities in rats. , 1983, Journal of pharmacobio-dynamics.

[16]  S. Pond,et al.  First-Pass Elimination Basic Concepts and Clinical Consequences , 1984, Clinical pharmacokinetics.

[17]  J. Young,et al.  STUDIES ON THE ABSORPTION, METABOLISM AND EXCRETION OF METHYLDOPA AND OTHER CATECHOLS AND THEIR INFLUENCE ON AMINO ACID TRANSPORT IN RATS. , 1964, The Journal of pharmacology and experimental therapeutics.

[18]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[19]  R. Kapil,et al.  Nonlinear bioavailability of metoclopramide in the rat: evidence for saturable first-pass metabolism. , 1984, Journal of pharmaceutical sciences.

[20]  M. Kasuga,et al.  Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[21]  Patrick J. Sinko,et al.  Predicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach , 1991, Pharmaceutical Research.

[22]  J. Kolars,et al.  CYP3A gene expression in human gut epithelium. , 1994, Pharmacogenetics.

[23]  H. Lennernäs,et al.  The Influence of Net Water Absorption on the Permeability of Antipyrine and Levodopa in the Human Jejunum , 1994, Pharmaceutical Research.

[24]  Mort Rosenberg,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th Edition. , 2003 .

[25]  M. Hussain,et al.  Buccal and oral bioavailability of nalbuphine in rats. , 1986, Journal of pharmaceutical sciences.

[26]  C. Beglinger,et al.  MAPPING OF MULTIDRUG RESISTANCE GENE 1 AND MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN ISOFORM 1 TO 5 mRNA EXPRESSION ALONG THE HUMAN INTESTINAL TRACT , 2005, Drug Metabolism and Disposition.

[27]  Y. Sugiyama,et al.  Expression and localization of the multidrug resistance-associated protein 3 in rat small and large intestine. , 2002, American journal of physiology. Gastrointestinal and liver physiology.

[28]  L. F. Chasseaud,et al.  Isosorbide 5‐mononitrate kinetics , 1984, Clinical pharmacology and therapeutics.

[29]  G. Castañeda-Hernández,et al.  Ingestion of chilli pepper (Capsicum annuum) reduces salicylate bioavailability after oral asprin administration in the rat. , 1999, Canadian journal of physiology and pharmacology.

[30]  S. Connolly,et al.  Clinical Pharmacokinetics of N-acetylprocainamide , 1982, Clinical pharmacokinetics.

[31]  R. Mehvar,et al.  Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[32]  K. C. Kwan,et al.  Pharmacokinetics of methyldopa in man. , 1976, The Journal of pharmacology and experimental therapeutics.

[33]  F. Jamali,et al.  Clinical Pharmacokinetics of Ketoprofen and Its Enantiomers , 1990, Clinical pharmacokinetics.

[34]  D. Richards Comparative Pharmacodynamics and Pharmacokinetics of Cimetidine and Ranitidine , 1983, Journal of clinical gastroenterology.

[35]  H. Lennernäs,et al.  Rat Jejunal Permeability and Metabolism of μ-Selective Tetrapeptides in Gastrointestinal Fluids from Humans and Rats , 1997, Pharmaceutical Research.

[36]  K. Fotherby Levonorgestrel. Clinical pharmacokinetics. , 1995, Clinical pharmacokinetics.

[37]  R. Foster,et al.  PHARMACOKINETICS OF THE ENANTIOMERS OF VERAPAMIL AFTER INTRAVENOUS AND ORAL ADMINISTRATION OF RACEMIC VERAPAMIL IN A RAT MODEL , 1997, Biopharmaceutics & drug disposition.

[38]  Anne Hersey,et al.  Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. , 2003, European journal of medicinal chemistry.

[39]  M. Manns,et al.  Polymorphic Gene Regulation and Interindividual Variation of UDP-glucuronosyltransferase Activity in Human Small Intestine* , 2000, The Journal of Biological Chemistry.

[40]  D. Keppler,et al.  ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. , 1997, The Biochemical journal.

[41]  H. Lennernäs,et al.  The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum. , 1995, Journal of drug targeting.

[42]  J. Noordhoek,et al.  Distribution of glucuronidation capacity (1-naphthol and morphine) along the rat intestine. , 1985, Biochemical pharmacology.

[43]  D. McTavish,et al.  Verapamil , 2012, Drugs.

[44]  P. Fagiolino,et al.  Bioavailability study of furosemide prodrugs in rats. , 1992, Farmaco.

[45]  W. L. Chiou The validation of the intestinal permeability approach to predict oral fraction of dose absorbed in humans and rats. , 1995, Biopharmaceutics & drug disposition.

[46]  J. Reid,et al.  The metabolism and kinetics of doxazosin in man, mouse, rat and dog. , 1986, British journal of clinical pharmacology.

[47]  M. Hayashi,et al.  A possibility to predict the absorbability of poorly water-soluble drugs in humans based on rat intestinal permeability assessed by an in vitro chamber method. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[48]  H. Lennernäs,et al.  Regional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man , 1995, Pharmaceutical Research.

[49]  S. Nylander,et al.  Jejunal Permeability: A Comparison Between the Ussing Chamber Technique and the Single-Pass Perfusion in Humans , 1997, Pharmaceutical Research.

[50]  D. Dunbar,et al.  Characterization of human small intestinal cytochromes P-450. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[51]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[52]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[53]  B. Steffansen,et al.  Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[54]  L. Benet,et al.  Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. , 2002, The Journal of pharmacology and experimental therapeutics.

[55]  G. Amidon,et al.  Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. , 2002, Journal of pharmaceutical sciences.

[56]  G. Amidon,et al.  Intestinal absorption of amino acid derivatives: importance of the free alpha-amino group. , 1982, Journal of pharmaceutical sciences.

[57]  M. Hümpel,et al.  Terminal half-lives in plasma and bioavailability of norethisterone, levonorgestrel, cyproterone acetate and gestodene in rats, beagles and rhesus monkeys☆ , 1981 .

[58]  J. Kolars,et al.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.

[59]  H. Lennernäs,et al.  The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. , 1999, British journal of clinical pharmacology.

[60]  C. Beglinger,et al.  Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation , 1996, British journal of pharmacology.

[61]  G. Amidon,et al.  Correlation between epithelial cell permeability of cephalexin and expression of intestinal oligopeptide transporter. , 2001, Journal of Pharmacology and Experimental Therapeutics.

[62]  Lawrence X. Yu,et al.  In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. , 2004, Current opinion in drug discovery & development.

[63]  P. Beaune,et al.  Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. , 1990, The Journal of pharmacology and experimental therapeutics.

[64]  M. Mattila,et al.  Pharmacokinetics of Oxicam Nonsteroidal Anti-Inflammatory Agents , 1994, Clinical pharmacokinetics.

[65]  G. Amidon,et al.  Human Jejunal Permeability of Two Polar Drugs: Cimetidine and Ranitidine , 2001, Pharmaceutical Research.

[66]  W. Rubas,et al.  Comparison of the Permeability Characteristics of a Human Colonic Epithelial (Caco-2) Cell Line to Colon of Rabbit, Monkey, and Dog Intestine and Human Drug Absorption , 2004, Pharmaceutical Research.

[67]  P. Brooks,et al.  Clinical Pharmacokinetics of the Salicylates , 1985, Clinical pharmacokinetics.

[68]  S. Adibi The oligopeptide transporter (Pept-1) in human intestine: biology and function. , 1997, Gastroenterology.

[69]  Gordon L. Amidon,et al.  Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.

[70]  Y. Sugiyama,et al.  cDNA cloning and inducible expression of human multidrug resistance associated protein 3 (MRP3). , 1998, FEBS letters.

[71]  H Lennernäs,et al.  Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 1998, Journal of medicinal chemistry.

[72]  C. Rozé,et al.  Chronic nifedipine dosing enhances cephalexin bioavailability and intestinal absorption in conscious rats. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[73]  Hans Lennernäs,et al.  Jejunal Absorption and Metabolism of R/S-Verapamil in Humans , 1998, Pharmaceutical Research.

[74]  A. Barve,et al.  Linear Correlation of the Fraction of Oral Dose Absorbed of 64 Drugs Between Humans and Rats , 1998, Pharmaceutical Research.

[75]  G. Amidon,et al.  Human Intestinal Permeability of Piroxicam, Propranolol, Phenylalanine, and PEG 400 Determined by Jejunal Perfusion , 1997, Pharmaceutical Research.

[76]  G. Amidon,et al.  Gene Expression in the Human Intestine and Correlation with Oral Valacyclovir Pharmacokinetic Parameters , 2003, Journal of Pharmacology and Experimental Therapeutics.

[77]  M. Holdiness,et al.  Clinical Pharmacokinetics of the Antituberculosis Drugs , 1984, Clinical pharmacokinetics.

[78]  G. Amidon,et al.  Passive and Carrier-Mediated Intestinal Absorption Components of Two Angiotensin Converting Enzyme (ACE) Inhibitor Prodrugs in Rats: Enalapril and Fosinopril , 1989, Pharmaceutical Research.